参考文献: [1]Antoine I., Benjamin B., Hossein B. et al. Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim ...
A2A-005试验剂量探索阶段结果:Inupadenant联合化疗治疗免疫检查点抑制剂治疗后进展的非鳞状NSCLC患者的疗效 Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Thera...
Successful intraosseous therapy using EZ-IO system in a preterm neonate below 2 kg. Minerva Pediatr 2018;70(1):104-5. doi:10.23736/S0026-4946.16.04707-1. (Croatia) This paper is a letter to the editor describing successful insertion of EZ-IO in a neonate weighing less than 2 kg with ...
He added that he would "love to learn which patients can stop therapy and when, or whether we can do infrequent maintenance IO [immonotherapy]." https://twitter.com/JackWestMD/status/1074006348243718144?s=20 Nivolumab Survival Data The data on nivolumab come from a pooled analysis of 5-...
In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer. Listen Amivantamab/Lazertinib Efficacy in EGFR+ NSCLC Sustained in MARIPOSA Follow-Up ...
We observed that SPP1 + SIRPα + macrophages demonstrated the high- est expression levels of CD274, CD80, and CD86 com- pared with other TAM subtypes (Fig. 5N), potentially contributing to the increased response rate to immu- notherapy. The potential crosstalk among tumor cells,...
Median durations of therapy were 7.1 months with the doublet and 7.8 months with the triplet. A little more than two-thirds of patients (69%) were white and one-fourth were Asian. In the doublet and triplet arms, respectively, 53% and 66% of patients had received prior sorafenib, and ...
英文标题:Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial 中文标题:在免疫检查点抑制剂治疗或治...
Methods: A prospective nested case-control study was performed to investigate markers of MMR revaccination induced humoral and cell- mediated immunity in 15 patients with juvenile idiopathic arthritis (ages 6-17 years), treated with either low-dose Methotrexate (MTX) therapy alone or in combination...
The term “treatment” as used herein in the context of treating a condition or disorder, pertains generally to treatment and therapy in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progr...